Chief Editor and Editors play a vital role in maintaining standards of journal through peer review process. Editors should make sure that all the articles must be published with respect to the scope of the journal according to scientific relevancy, veracity, Research strength, innovative methods. Editors must be unbiased with his decisions given on manuscripts and that should not be affected by the author’s nativity, nationality, ethnicity, religion etc. Manuscript judgment must support the scientific validity and significance to the scientific world.
After receiving manuscripts from author, editorial office assigns the manuscript to an editor to review the manuscript. Papers are assigned to editors based on their expertise and research interest. Editor’s role is to assign two reviewers to provide review comments. In a situation where editor cannot assign reviewers, then editorial office assigns the reviewers on behalf of editor. Editor should respond timely on his timeline in completing the peer review process and providing his decisions on manuscripts. Editor has to supervise the entire peer review cycle to preserve the principles of the journal. Editor can handle any number manuscripts for peer review process according to his interest and other commitments. As the editors are back bone to journal sustainability, editors can contribute the manuscripts which can be research articles/ editorials/ short communications for continuation of issues in the journal. Editor has to encourage the submissions from other qualified authors and they can suggest their colleagues. We welcome our editors to suggest us new thoughts and ideas for the advancement of the journal. Editors need to ensure the security of individual data and maintain privacy.
Published : 01st November 2019
Authors : Bin Wang1,2, Jianhua Ren3, Peng Zhang4, Dusica Cvetkovic1, Xiaoming Chen1, Lili Chen1, and Chang-Ming Charlie Ma1
Citation : Ma CM. (2019). An In-Vivo Study on Pulsed Low-Dose-Rate Radiotherapy for Prostate Cancer. Mathews J Cancer Sci. 4(2): 21.
Published : 17th June 2019
Authors : Reger R. Mikaeel1,2,3,4 , Timothy J. Price1,3, Eric Smith1,5, Paul A. Drew5, Wendy Uylaki1,6, Mehgan Horsnell1, Joanne P. Young1,2,3
Citation : Mikaeel RR. (2019). Colorectal Cancer in Australian Young Adults. Mathews J Cancer Sci. 4(1): 18
Published : 17th March 2019
Authors : Jiancang Wang*, Feifan Du, Ming Su, Xiting Guo, Haixia Tian, Yanxia Song, Liya shang, Wei Zheng, Xiaoge Yang
Citation : Wang J. (2019). Cytomegalovirus Retinitis in a 4-Year-Old Child with Acute Lymphoblastic Leukemia: Treatment and Prognosis. Mathews J Cancer Sci. 4(1): 17
Published : 30th November 2018
Authors : Yang Yang1,3, Olagoke Zacchaeus Olatunde2 , Jianping Yong1 *, Canzhong Lu1,2*
Citation : Yang Y, Olatunde OZ, Yong J and Lu C. (2018). Progress of Chemical Components and Biological Activities of Lonicera Maackii. Mathews J Cancer Sci. 3(1): 016.
Published : 12th November 2018
Authors : Mahdis Solhjoo1*,Alireza Rastgoo Haghi2,Nasim Golchin3,Negar Golchin4,Roham Shahbazi2
Citation : Solhjoo M, Haghi AR, Golchin N, Golchin N, et al. (2018). Expression of E-cadherin and Ki-67 in Gastric Cancer Patients and Cor- relation with Clinicopathological Factors.Mathews J Cancer Sci. 3(1): 015
Published : 18th September 2018
Author : Jussara Maria Gonçalves1 *
Citation : Gonçalves JM. (2018). Cancer Stem Cells: Current Challenge in Cancer Treatment and Important Prognosis Factor.Mathews J Cancer Sci. 3(1): e001
Published : 26th February 2018
Author : Dennis Stamp1*
Citation : Stamp D. (2018). Suggested Model to Induce Esophageal Cancer and Its Precursor Lesions in the Esophagus of Rats. Mathews J Cancer Sci. 3(1): 014.
Published : 27th April 2017
Author : Daniela Capdepón*
Citation : Capdepón D. (2017). Advances in the Care of Diabetes and Cancer. Mathews J Cancer Sci. 2(1): 013.
Published : 01st March 2017
Authors : Aurelio B. Castrellon*, Steven M. Nguyen, Adriana M. Milillo Naraine, Michel Velez, Luis E. Raez
Citation : Castrellon AB, Nguyen SM, Milillo Naraine AM, Velez M, et al. (2017). Initial Response to Therapy with Fulvestrant and Cyclin-Dependent Kinase 4/6 Inhibitor in a Male with Stage IV Breast Cancer.Mathews J Cancer Sci. 2(1): 012.